TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
EUDA Health Holdings ( (EUDA) ) has shared an announcement.
On September 10, 2025, EUDA Health Holdings announced that its subsidiary, EUDA Health Pte. Ltd., signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore. This acquisition would allow EUDA to expand into the iPSC solutions market, with plans to establish a laboratory in Shenzhen, China, and collaborate with A*STAR to advance iPSC research. This strategic move positions EUDA to supply B2B iPSC solutions to healthcare ecosystems, enhancing its portfolio in regenerative health and opening new opportunities in Asia’s wellness markets.
The most recent analyst rating on (EUDA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on EUDA Health Holdings stock, see the EUDA Stock Forecast page.
More about EUDA Health Holdings
EUDA Health Holdings Limited is a Singapore-based leading non-invasive healthcare provider in Asia, focusing on markets in Singapore, Malaysia, and China. The company aims to lead in non-invasive and preventive healthcare, particularly in the longevity sector, addressing the needs of over 1.8 billion people in a region experiencing significant demographic shifts.
Average Trading Volume: 92,313
Technical Sentiment Signal: Sell
Current Market Cap: $55.73M
See more data about EUDA stock on TipRanks’ Stock Analysis page.